See more : Dian Diagnostics Group Co.,Ltd. (300244.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Puma Biotechnology, Inc. (PBYI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Puma Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shantou Wanshun New Material Group Co., Ltd. (300057.SZ) Income Statement Analysis – Financial Results
- Avidbank Holdings, Inc. (AVBH) Income Statement Analysis – Financial Results
- Archon Minerals Limited (AHNMF) Income Statement Analysis – Financial Results
- Orpheum Property, Inc. (PLFF) Income Statement Analysis – Financial Results
- Yunnan Energy International Co. Limited (1298.HK) Income Statement Analysis – Financial Results
Puma Biotechnology, Inc. (PBYI)
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 235.64M | 228.00M | 253.20M | 225.10M | 272.30M | 251.00M | 27.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -281.10K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 62.68M | 55.10M | 63.70M | 39.40M | 36.80M | 34.60M | 5.60M | 1.15M | 776.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 172.96M | 172.90M | 189.50M | 185.70M | 235.50M | 216.40M | 22.10M | -1.15M | -776.00K | 0.00 | 0.00 | 0.00 | -281.10K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 73.40% | 75.83% | 74.84% | 82.50% | 86.49% | 86.22% | 79.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 50.38M | 52.20M | 71.90M | 97.70M | 132.90M | 164.90M | 207.80M | 222.80M | 208.50M | 122.90M | 45.05M | 49.60M | 826.37K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 88.43M | 89.98M | 116.29M | 118.49M | 140.51M | 146.19M | 106.70M | 53.80M | 31.80M | 19.40M | 9.79M | 24.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 881.00K | 22.00K | 6.00K | -88.00K | 1.19M | 12.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 89.31M | 90.00M | 116.30M | 118.40M | 141.70M | 146.20M | 106.70M | 53.80M | 31.80M | 19.40M | 9.79M | 24.80M | 9.32M | 15.98K | 16.84K | 14.08K | 0.00 |
| Other Expenses | 625.00K | -28.00K | 300.00K | 400.00K | 200.00K | -9.70M | -100.00K | -400.00K | 25.00K | -14.00K | 2.00K | 293.00K | 10.70K | 0.00 | 0.00 | 0.00 | -15.09M |
| Operating Expenses | 140.32M | 142.20M | 188.20M | 216.10M | 274.60M | 311.10M | 314.50M | 276.60M | 240.30M | 142.30M | 54.83M | 74.40M | 10.16M | 15.98K | 16.84K | 14.08K | -15.09M |
| Cost & Expenses | 203.00M | 197.30M | 251.90M | 255.50M | 311.40M | 345.70M | 320.10M | 276.60M | 240.30M | 142.30M | 54.83M | 74.40M | 10.16M | 15.98K | 16.84K | 14.08K | -15.09M |
| Interest Income | 2.61M | 800.00K | 100.00K | 500.00K | 2.80M | 1.80M | 1.20M | 1.00M | 1.00M | 300.00K | 172.00K | 100.00K | 3.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.33M | 11.50M | 12.80M | 14.10M | 15.00M | 11.00M | 700.00K | 958.00K | 971.00K | 324.00K | 172.00K | 98.00K | 3.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 11.52M | 8.92M | 10.60M | 7.20M | 4.80M | 7.38M | 2.81M | 1.15M | 776.00K | 627.00K | 423.00K | 265.00K | 10.70K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 47.52M | 20.97M | -5.40M | -38.54M | -55.72M | -95.21M | -288.42M | -275.45M | -239.50M | -141.65M | -54.41M | -74.09M | -10.22M | -15.98K | -16.84K | -14.08K | -15.09M |
| EBITDA Ratio | 20.17% | 13.82% | 0.67% | -13.11% | -13.26% | -40.88% | -1,051.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,580.97% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 32.64M | 23.70M | -8.90M | -30.40M | -39.10M | -94.70M | -292.40M | -276.60M | -240.30M | -142.30M | -54.83M | -74.40M | -10.16M | -15.98K | -16.84K | -14.08K | -15.09M |
| Operating Income Ratio | 13.85% | 10.39% | -3.51% | -13.51% | -14.36% | -37.73% | -1,055.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,613.24% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -9.97M | -23.26M | -30.09M | -29.39M | 53.00K | -18.92M | 435.00K | 585.00K | 996.00K | 310.00K | 174.00K | 98.00K | -76.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 22.67M | 500.00K | -28.80M | -59.80M | -75.60M | -113.60M | -292.00M | -276.00M | -239.30M | -142.00M | -54.66M | -74.30M | -10.23M | -15.98K | -16.84K | -14.08K | -15.09M |
| Income Before Tax Ratio | 9.62% | 0.22% | -11.37% | -26.57% | -27.76% | -45.26% | -1,054.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,640.35% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.08M | 500.00K | 300.00K | 200.00K | 7.12M | -7.92M | -2.21M | -2.15M | -1.75M | -941.00K | -172.00K | -267.00K | 76.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 21.59M | 912.00K | -29.10M | -60.00M | -82.72M | -113.60M | -292.00M | -276.00M | -239.30M | -142.00M | -54.66M | -74.30M | -10.23M | -15.98K | -16.84K | -14.08K | -15.09M |
| Net Income Ratio | 9.16% | 0.40% | -11.49% | -26.65% | -30.38% | -45.26% | -1,054.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,640.35% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.46 | 0.02 | -0.72 | -1.52 | -2.13 | -2.99 | -7.86 | -8.29 | -7.45 | -4.73 | -1.90 | -3.42 | -0.51 | 0.00 | -0.01 | 0.00 | -0.38 |
| EPS Diluted | 0.45 | 0.02 | -0.72 | -1.52 | -2.13 | -2.99 | -7.86 | -8.29 | -7.45 | -4.73 | -1.90 | -3.42 | -0.51 | 0.00 | -0.01 | 0.00 | -0.38 |
| Weighted Avg Shares Out | 47.13M | 44.67M | 40.64M | 39.58M | 38.77M | 37.94M | 37.17M | 33.30M | 32.13M | 30.01M | 28.70M | 21.73M | 20.04M | 7.75M | 3.00M | 3.00M | 39.29M |
| Weighted Avg Shares Out (Dil) | 47.55M | 44.93M | 40.64M | 39.58M | 38.77M | 37.94M | 37.17M | 33.30M | 32.13M | 30.01M | 28.70M | 21.73M | 20.04M | 7.75M | 3.00M | 3.00M | 39.29M |
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported findings from a Phase I/II study of Alisertib and pembrolizumab for Rb-Deficient HNSCC at the 2023 AACR-NCI-EORTC meeting.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 2, 2023, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common...
Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC
Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--The FDA has granted Orphan Drug Designation to Puma Biotechnology's drug candidate alisertib for the treatment of small cell lung cancer.
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO of Puma Biotechnology, will present a corporate update at the H.C. Wainwright Global Investment Conference beginning on 9/11/23.
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma has been notified by the FDA that its IND has been reviewed, and Puma can proceed with clinical development of alisertib monotherapy for SCLC.
Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform
Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.
Puma Biotechnology, Inc. (PBYI) Q2 2023 Earnings Call Transcript
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Chairman, President and CEO Maximo Nougues - CFO Jeff Ludwig - CCO Conference...
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
Puma Biotech (PBYI) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.21 per share a year ago.
Puma Biotechnology Reports Second Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 2Q'23 earnings release on Aug. 3 and hosted a call at 4:30 pm ET to discuss results.
Source: https://incomestatements.info
Category: Stock Reports